留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

胰腺癌循环肿瘤细胞检测技术及临床应用前景

杨笑盈 秦骋 赵邦博 李天浩 曹洪滔 王维斌

杨笑盈, 秦骋, 赵邦博, 李天浩, 曹洪滔, 王维斌. 胰腺癌循环肿瘤细胞检测技术及临床应用前景[J]. 协和医学杂志, 2021, 12(5): 768-773. doi: 10.12290/xhyxzz.2020-0005
引用本文: 杨笑盈, 秦骋, 赵邦博, 李天浩, 曹洪滔, 王维斌. 胰腺癌循环肿瘤细胞检测技术及临床应用前景[J]. 协和医学杂志, 2021, 12(5): 768-773. doi: 10.12290/xhyxzz.2020-0005
YANG Xiaoying, QIN Cheng, ZHAO Bangbo, LI Tianhao, CAO Hongtao, WANG Weibin. Detection Technology and Prospects of Clinical Application of Circulating Tumor Cells in Pancreatic Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 768-773. doi: 10.12290/xhyxzz.2020-0005
Citation: YANG Xiaoying, QIN Cheng, ZHAO Bangbo, LI Tianhao, CAO Hongtao, WANG Weibin. Detection Technology and Prospects of Clinical Application of Circulating Tumor Cells in Pancreatic Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 768-773. doi: 10.12290/xhyxzz.2020-0005

胰腺癌循环肿瘤细胞检测技术及临床应用前景

doi: 10.12290/xhyxzz.2020-0005
基金项目: 

国家自然科学基金 81773215

详细信息
    通讯作者:

    王维斌  电话:010-69152610,E-mail: wwb_xh@163.com

  • 中图分类号: R735.9

Detection Technology and Prospects of Clinical Application of Circulating Tumor Cells in Pancreatic Cancer

Funds: 

National Natural Science Foundation of China 81773215

More Information
    Corresponding author: WANG Weibin  Tel: 86-10-69152610, E-mail: wwb_xh@163.com
  • 摘要: 胰腺癌是消化系统高度恶性的肿瘤之一,其早期即可发生远处转移,患者生存期较短、预后较差。循环肿瘤细胞(circulating tumor cells, CTCs)是一类可进入血液循环的肿瘤细胞,不仅具有与原发肿瘤细胞相似的特征,且与肿瘤远处转移的关系更为密切。体外定量检测CTCs对胰腺癌的早期诊断、辅助分期、疗效及预后评估均具有重要意义。本文对胰腺癌CTCs富集方法及CTCs检测在胰腺癌筛查、远处转移与预后评估中的应用进行综述。
    作者贡献:  杨笑盈、秦骋撰写论文初稿;王维斌负责论文设计;赵邦博负责论文修改;李天浩、曹洪滔负责文献查阅工作;所有作者均参与本文修订。
    利益冲突:
  • [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70: 7-30. doi:  10.3322/caac.21590
    [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66: 115-232. doi:  10.3322/caac.21338
    [3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68: 7-30. doi:  10.3322/caac.21442
    [4] Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT[J]. Radiology, 2011, 260: 446-453. doi:  10.1148/radiol.11103548
    [5] Becker AE, Hernandez YG, Frucht H, et al. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection[J]. World J Gastroenterol, 2014, 20: 11182-11198. doi:  10.3748/wjg.v20.i32.11182
    [6] Lee J, Park SS, Lee YK, et al. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA[J]. Mol Oncol, 2019, 13: 1623-1650. doi:  10.1002/1878-0261.12537
    [7] Malafa MP, Permuth J, Chen D. MicroRNA assay for detection and management of pancreatic cancer precursors[P]. U.S. Patent, 2019, 10: 240.
    [8] Yang ZJ, LaRiviere MJ, Ko J, et al. A multi-analyte panel consisting of extracellular vesicle miRNAs and mRNAs, cfDNA, and CA19-9 shows utility for diagnosis and staging of pancreatic adenocarcinoma[J]. Clin Cancer Res, 2020, 26: 3248-3258. doi:  10.1158/1078-0432.CCR-19-3313
    [9] Bernard V, Kim DU, San LFA, et al. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer[J]. Gastroenterology, 2019, 156: 108-118. doi:  10.1053/j.gastro.2018.09.022
    [10] Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Aust Med J, 1869, 14: 146.
    [11] 乔雪峰, 张玉娟, 崔巍. 循环肿瘤细胞致肿瘤血行转移研究进展[J]. 协和医学杂志, 2014, 5: 331-334. doi:  10.3969/j.issn.1674-9081.2014.03.017
    [12] Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells[J]. Nat Rev Cancer, 2008, 8: 329-340. doi:  10.1038/nrc2375
    [13] Vaidyanathan R, Soon RH, Zhang P, et al. Cancer diagnosis: from tumor to liquid biopsy and beyond[J]. Lab Chip, 2018, 19: 11-34. http://www.ncbi.nlm.nih.gov/pubmed/30480287
    [14] Hao S, Wan Y, Xia Y, et al. Size-based separation methods of circulating tumor cells[J]. Adv Drug Deliv Rev, 2018, 125: 3-20. doi:  10.1016/j.addr.2018.01.002
    [15] Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells[J]. Am J Pathol, 2000, 156: 57-63. doi:  10.1016/S0002-9440(10)64706-2
    [16] Burinaru TA, Avram M, Avram A, et al. Detection of Circulating Tumor Cells Using Microfluidics[J]. ACS Comb Sci, 2018, 20: 107-126. doi:  10.1021/acscombsci.7b00146
    [17] Riethdorf S, O'Flaherty L, Hille C, et al. Clinical applications of the CellSearch platform in cancer patients[J]. Adv Drug Deliv Rev, 2018, 125: 102-121. doi:  10.1016/j.addr.2018.01.011
    [18] Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas[J]. Hum Pathol, 2004, 35: 122-128. doi:  10.1016/j.humpath.2003.08.026
    [19] Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker[J]. Br J Cancer, 2012, 106: 508-516. doi:  10.1038/bjc.2011.545
    [20] 杨卓, 张玉娟, 陈倩, 等. 循环肿瘤细胞检测及其特性[J]. 协和医学杂志, 2013, 4: 191-194. doi:  10.3969/j.issn.1674-9081.2013.02.023
    [21] Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology[J]. Nature, 2007, 450: 1235-1239. doi:  10.1038/nature06385
    [22] Iwanicki-Caron I, Basile P, Toure E, et al. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis[J]. Am J Gastroenterol, 2013, 108: 152-155. doi:  10.1038/ajg.2012.367
    [23] Zhang W, Bao L, Yang S, et al. Tumor-selective replication herpes simplex virus-based technology signifi-cantly improves clinical detection and prognostication of viable circulating tumor cells[J]. Oncotarget, 2016, 7: 39768-39783. doi:  10.18632/oncotarget.9465
    [24] Chang C, Huang W, Jalal SI, et al. Circulating tumor cell detection using a parallel flow micro-aperture chip system[J]. Lab Chip, 2015, 15: 1677-1688. doi:  10.1039/C5LC00100E
    [25] Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148: 349-361. doi:  10.1016/j.cell.2011.11.025
    [26] Rhim AD, Thege FI, Santana SM, et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions[J]. Gastroenterology, 2014, 146: 647-651. doi:  10.1053/j.gastro.2013.12.007
    [27] Cauley CE, Pitman MB, Zhou J, et al. Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings[J]. J Am Coll Surg, 2015, 221: 699-707. doi:  10.1016/j.jamcollsurg.2015.05.014
    [28] Kamande JW, Hupert ML, Witek MA, et al. Modular microsystem for the isolation, enumeration, and phenotyping of circulating tumor cells in patients with pancreatic cancer[J]. Anal Chem, 2013, 85: 9092-9100. doi:  10.1021/ac401720k
    [29] Court CM, Ankeny JS, Sho S, et al. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer[J]. Ann Surg Oncol, 2018, 25: 1000-1008.
    [30] Kulemann B, Pitman MB, Liss AS, et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer[J]. Pancreas, 2015, 44: 547-550. doi:  10.1097/MPA.0000000000000324
    [31] Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen[J]. Cancer Control, 2008, 15: 280-287. doi:  10.1177/107327480801500402
    [32] Soeth E, Grigoleit U, Moellmann B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival[J]. J Cancer Res Clin Oncol, 2005, 131: 669-676. doi:  10.1007/s00432-005-0008-1
    [33] Kurihara T, Itoi T, Sofuni A, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result[J]. J Hepatobiliary Pancreat Surg, 2008, 15: 189-195. doi:  10.1007/s00534-007-1250-5
    [34] de Albuquerque A, Kubisch I, Breier G, et al. Multi-marker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study[J]. Oncology, 2012, 82: 3-10. doi:  10.1159/000335479
    [35] Bidard FC, Huguet F, Louvet C, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial[J]. Ann Oncol, 2013, 24: 2057-2061. doi:  10.1093/annonc/mdt176
    [36] Gao Y, Zhu Y, Zhang Z, et al. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization[J]. J Exp Clin Cancer Res, 2016, 35: 66. doi:  10.1186/s13046-016-0340-0
    [37] Poruk KE, Valero V, Saunders T, et al. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma[J]. Ann Surg, 2016, 264: 1073-1081. doi:  10.1097/SLA.0000000000001600
    [38] Stephenson D, Nahm C, Chua T, et al. Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8: 107223-107236. doi:  10.18632/oncotarget.19928
    [39] Effenberger KE, Schroeder C, Hanssen A, et al. Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer[J]. Clin Cancer Res, 2018, 24: 2844-2850. doi:  10.1158/1078-0432.CCR-18-0120
    [40] Chang M, Chang Y, Chen J, et al. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma[J]. Clin Chem, 2016, 62: 505-513. doi:  10.1373/clinchem.2015.248260
    [41] Catenacci DV, Chapman CG, Xu P, et al. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound[J]. Gastroenterology, 2015, 149: 1794-1803. doi:  10.1053/j.gastro.2015.08.050
    [42] Bissolati M, Sandri MT, Burtulo G, et al. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer[J]. Tumour Biol, 2015, 36: 991-996. doi:  10.1007/s13277-014-2716-0
    [43] Tien YW, Kuo H, Ho B, et al. A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver Metastases[J]. Medicine (Baltimore), 2016, 95: e3407. doi:  10.1097/MD.0000000000003407
    [44] Nagrath S, Jack RM, Sahai V, et al. Opportunities and Challenges for Pancreatic Circulating Tumor Cells[J]. Gastroenterology, 2016, 151: 412-426. doi:  10.1053/j.gastro.2016.05.052
  • 加载中
计量
  • 文章访问数:  130
  • HTML全文浏览量:  26
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-03
  • 录用日期:  2020-12-28
  • 网络出版日期:  2021-02-05
  • 刊出日期:  2021-10-12

目录

    /

    返回文章
    返回